INVO Fertility (IVF) Q2 2026 earnings summary

Executive summary

• Q2 2026 revenue increased 18% year-over-year to $2.2 million, driven by the addition of the Indiana Clinic and organic growth.

• Net income for Q2 2026 was $0.9 million, reversing a net loss of $3.6 million in Q2 2025, aided by gains from business combinations.

• The company completed the acquisition of Family Beginnings (Indiana Clinic) in February 2026 and full ownership of the Birmingham/Alabama JV in June 2026, expanding to four U.S. clinics.

• Clinic platform achieved profitability on an Adjusted EBITDA basis before corporate and public company expenses.

• A warrant inducement in January 2026 raised $7.1 million, supporting acquisition payments and debt reduction.

Financial highlights

• Q2 2026 revenue: $2.2 million (up from $1.8 million in Q2 2025); six-month revenue: $4.2 million (up from $3.5 million in 2025).

• Q2 2026 net income: $0.9 million; six-month net loss: $4.7 million (improved from $21.0 million loss in 2025).

• Clinic-Level Adjusted EBITDA was $333,000 in Q2 2026, up from $164,000 in Q1 2026.

• Cash at June 30, 2026: $3.7 million (up from $0.5 million in 2025); stockholders' equity: $16.5 million (up from $7.2 million at year-end 2025).

• Cost of services increased to $1.4 million, mainly due to the Family Beginnings acquisition and one-time staffing costs.

Outlook and guidance

• Plans to grow clinic revenue organically and through additional profitable fertility clinic acquisitions.

• Ongoing focus on expanding the clinic network and leveraging the INVOcell device within and outside company-owned clinics.

• Substantial doubt remains about the ability to continue as a going concern without additional funding; management is actively seeking further debt and equity financing.